MaxCyte Q2 revenue down 6% YoY, core revenue down 14%; expects 2023 core revenue flat to 2022

MAXCYTE, INC.

2023-Q2 EPS reported -$0.21 revenue$17,618,900

Total revenue $9.0M in Q2 2023 (-6% YoY); core business revenue $8.3M (-14% YoY).
Net loss $10.5M in Q2 vs $8.3M loss in Q2 2022; EBITDA loss $12.0M vs $8.2M.
FY2023 guidance: core revenue now expected comparable to 2022 (flat); SPL program revenue unchanged ~$6M.
Five SPL partnerships signed YTD including Lyell, ViTToria, Prime Medicine; total SPLs at 23.
Cash and investments $216.1M as of June 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAXCYTE, INC. reported the quarter ended June 30, 2023 results: revenue $9.0 million, net income $10.5 million. Guidance reaffirmed.

Period: the quarter ended June 30, 2023
Revenue: $9.0 million
Net income: $10.5 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the second quarter of 2023 was $9.0 million, compared to $9.6 million in the second quarter of 2022, representing a decline of 6%.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAXCYTE, INC. reported the six months ended June 30, 2023 results: revenue $17.6 million, net income $21.4 million. Guidance reaffirmed.

Period: the six months ended June 30, 2023
Revenue: $17.6 million
Net income: $21.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the first half of 2023 was $17.6 million, compared to $21.2 million in the first half of 2022, representing a decline of 17%.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-014270

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.